STOCK TITAN
  1. Home
  2. Sec-filings
  3. VMD
  4. [Form 4] VIEMED HEALTHCARE, INC. Insider Trading Activity

Viemed Healthcare (VMD) VP logs RSU and phantom unit vesting with tax share withholding

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Viemed Healthcare Vice President of Sales Cambre Jerome reported equity award activity and related share transactions. On January 21, 2026, 11,719 Restricted Stock Units (RSUs) vested and were settled into an equal number of common shares, consistent with each RSU representing one common share. To cover taxes from this vesting, the issuer withheld 3,827 common shares at a per-share value of $7.49, based on the market closing price for that date.

The filing also shows vesting of 2,930 cash-settled phantom share units granted under Viemed’s Phantom Share Unit Plan, which are economically equivalent to common shares. The settlement is reported as an exchange of phantom shares for the underlying common shares and a simultaneous disposition of those common shares back to the company for cash. After these transactions, Jerome directly beneficially owned 97,824 common shares, as well as 23,436 RSUs and 5,859 phantom share units that remain outstanding.

Positive

  • None.

Negative

  • None.
Insider Cambre Jerome
Role Vice President of Sales
Type Security Shares Price Value
Exercise Restricted Stock Units 11,719 $0.00 --
Exercise Phantom Share Units 2,930 $0.00 --
Exercise Common Shares 11,719 $0.00 --
Tax Withholding Common Shares 3,827 $7.49 $29K
Exercise Common Shares 2,930 $0.00 --
Disposition Common Shares 2,930 $7.49 $22K
Holdings After Transaction: Restricted Stock Units — 23,436 shares (Direct); Phantom Share Units — 5,859 shares (Direct); Common Shares — 101,651 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units. Per share value is based on the market closing price of the common shares for January 21, 2026. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash. Restricted Stock Units (RSUs) granted to reporting person on January 21, 2025, which vest in three equal annual installments beginning on the first anniversary of the grant date. Represents an award granted on January 21, 2025 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cambre Jerome
(Last) (First) (Middle)
625 E. KALISTE SALOOM RD.
(Street)
LAFAYETTE LA 70508
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Vice President of Sales
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 01/21/2026 M 11,719 A (1) 101,651 D
Common Shares 01/21/2026 F 3,827(2) D $7.49(3) 97,824 D
Common Shares 01/21/2026 M 2,930 A (4) 100,754 D
Common Shares 01/21/2026 D 2,930 D $7.49(3) 97,824 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 01/21/2026 M 11,719 (5) 01/21/2028 Common Shares 11,719 $0 23,436 D
Phantom Share Units (4) 01/21/2026 M 2,930 (6) 01/21/2028 Common Shares 2,930 (4) 5,859 D
Explanation of Responses:
1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.
2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.
3. Per share value is based on the market closing price of the common shares for January 21, 2026.
4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.
5. Restricted Stock Units (RSUs) granted to reporting person on January 21, 2025, which vest in three equal annual installments beginning on the first anniversary of the grant date.
6. Represents an award granted on January 21, 2025 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Remarks:
/s/ Jesse Bergeron, Attorney-in-Fact 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in Viemed Healthcare (VMD)'s latest Form 4 filing?

The insider is Cambre Jerome, who serves as Vice President of Sales at Viemed Healthcare, Inc. and is the reporting person for the transactions disclosed.

What RSU activity did Cambre Jerome report in this Viemed Healthcare (VMD) Form 4?

Cambre Jerome reported the vesting and exercise (code M) of 11,719 Restricted Stock Units on January 21, 2026, with each RSU converting into one common share, and 23,436 RSUs remaining beneficially owned afterward.

How many Viemed Healthcare (VMD) shares were withheld for taxes in this Form 4?

The company withheld 3,827 common shares (transaction code F) to satisfy Cambre Jerome’s tax obligations arising from RSU vesting, using a per-share value of $7.49, the market closing price on January 21, 2026.

What are the phantom share unit transactions reported for Viemed Healthcare (VMD)?

The filing reports vesting (code M) of 2,930 phantom share units under Viemed’s Phantom Share Unit Plan. Each phantom share is economically equivalent to one common share, and settlement is reported as acquisition of underlying common shares and an immediate disposition of those shares back to the company for cash, leaving 5,859 phantom share units outstanding.

How many Viemed Healthcare (VMD) common shares does Cambre Jerome own after these transactions?

After all reported transactions on January 21, 2026, Cambre Jerome directly beneficially owned 97,824 Viemed Healthcare common shares, according to the Form 4.

Are the equity awards in this Viemed Healthcare (VMD) Form 4 part of a vesting schedule?

Yes. Footnotes state that the RSUs and phantom share units were granted on January 21, 2025 and each award vests in three equal annual installments beginning on the first anniversary of the grant date.